IMVIONIX Acquires BEOVU Commercial Rights in the United States and Canada
Key Facts
IMVIONIX announced on November 10, 2026, that it had acquired exclusive commercial rights to Novartis’ BEOVU in the United States and Canada, a move it described as its official commercial launch and first strategic deal. In a statement published via PR Newswire, the company said the agreement makes it the holder of the marketing license for the drug in both countries. IMVIONIX did not disclose the deal’s financial terms. Marketing of an approved treatment in two major markets is thus moving to a recently established company, while the agreement’s value remains undisclosed. The drug is used to treat two retinal conditions associated with vision loss.
BEOVU, whose generic name is brolucizumab, is a vascular endothelial growth factor inhibitor administered by intravitreal injection, according to IMVIONIX’s statement. Its approved uses include wet age-related macular degeneration and diabetic macular edema. The company describes the two conditions as leading causes of irreversible vision loss. The drug received its original U.S. approval on October 7, 2019, according to the U.S. Food and Drug Administration’s Purple Book database, under biologics license application number 761125. Novartis also said the drug received U.S. approval to treat diabetic macular edema in the second quarter of 2022, after its approval for wet age-related macular degeneration.
The North American commercial rights add to the development of BEOVU sales since its launch, with Novartis recording sales of $200 million in 2022. Sales rose 9% in U.S. dollars and 18% at constant currencies that year, according to the company’s annual report. Growth came as sales increased in Europe, emerging markets and Japan, while a decline in the United States partly offset those gains. The deal announcement did not state Novartis’ reasons for transferring the rights or describe the move as part of a routine portfolio adjustment. The deal therefore leaves IMVIONIX responsible for marketing in the United States and Canada, without disclosure of financial consideration or details of the commercial arrangements.
IMVIONIX was founded in 2025 by the former executive management team of Alimera Sciences, in collaboration with Caligan Partners and Velan Capital, according to the company’s statement. It said the founding team brings 60 years of experience in ophthalmology. The BEOVU deal is the company’s first strategic agreement, as it described it, and gives it the marketing license for an existing drug in the United States and Canada. The move focuses on marketing a treatment that is already approved, rather than submitting a new initial application for approval of the drug in the two countries. The statement gave no figures for IMVIONIX’s commercial plan or the size of the investment it will allocate to the launch.
The rights transfer comes as safety considerations cited in the drug’s official labeling remain relevant. The FDA has noted reports of retinal vasculitis or retinal vascular occlusion, usually in the presence of intraocular inflammation, following BEOVU injections. In June 2020, Novartis announced that the agency had approved a label update adding safety information about the two events, and said it had formed a team to review their causes, risk factors and ways to mitigate them. Other listed risks include endophthalmitis, retinal detachment and increased intraocular pressure, as well as the possibility of arterial thromboembolic events. The label states that the MERLIN study recorded an increase in intraocular inflammation, including retinal vasculitis and retinal vascular occlusion, among patients who received maintenance doses every 4 weeks compared with intervals of 8 or 12 weeks, and recommends that the maintenance interval be no shorter than 8 weeks.